Indaptus Therapeutics Inc... (INDP)
NASDAQ: INDP
· Real-Time Price · USD
0.47
-0.01 (-2.10%)
At close: Apr 29, 2025, 3:28 PM
0.51
8.26%
After-hours: Apr 29, 2025, 05:25 PM EDT
Company Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Indaptus Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 4, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey A. Meckler J.D. |
Contact Details
Address: 3 Columbus Circle New York, New York United States | |
| Website | https://indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J105 |
| ISIN Number | US45339J1051 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey A. Meckler J.D. | Chief Executive Officer & Director |
| Nir Sassi | Chief Financial Officer, Secretary & Treasurer |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | PRE 14A | Filing |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | POS AM | Filing |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | S-1 | Filing |
| Feb 12, 2025 | 8-K | Current Report |